

# Accepted Manuscript



High dose hypofractionated radiotherapy for non-compressive vertebral metastases in combination with zoledronate: a phase I study

Baptiste Pichon, MD, Loïc Campion, MD, Grégory Delpon, PhD, François Thillays, MD, MSc, Christian Carrie, MD, Patrice Cellier, MD, Pascal Pommier, MD, PhD, Cécile Laude, MD, Augustin Mervoyer, MD, Hadji Hamidou, MD, Marc-André Mahe, MD, PhD, Stéphane Supiot, MD, PhD

PII: S0360-3016(16)32906-6

DOI: [10.1016/j.ijrobp.2016.07.027](https://doi.org/10.1016/j.ijrobp.2016.07.027)

Reference: ROB 23736

To appear in: *International Journal of Radiation Oncology • Biology • Physics*

Received Date: 14 March 2016

Revised Date: 12 July 2016

Accepted Date: 25 July 2016

Please cite this article as: Pichon B, Campion L, Delpon G, Thillays F, Carrie C, Cellier P, Pommier P, Laude C, Mervoyer A, Hamidou H, Mahe M-A, Supiot S, High dose hypofractionated radiotherapy for non-compressive vertebral metastases in combination with zoledronate: a phase I study, *International Journal of Radiation Oncology • Biology • Physics* (2016), doi: [10.1016/j.ijrobp.2016.07.027](https://doi.org/10.1016/j.ijrobp.2016.07.027).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**High dose hypofractionated radiotherapy for non-compressive vertebral metastases in combination with zoledronate: a phase I study.**

**Running title:** phase 1 study of SBRT and zoledronate

*Baptiste PICHON, MD<sup>1</sup>, Loïc CAMPION, MD<sup>2</sup>, Grégory DELPON, PhD<sup>3,4</sup>, François THILLAYS, MD, MSc<sup>1</sup>, Christian CARRIE, MD<sup>5</sup>, Patrice CELLIER, MD<sup>6</sup>, Pascal POMMIER, MD, PhD,<sup>5</sup>, Cécile LAUDE, MD<sup>5</sup>, Augustin MERVOYER, MD<sup>1</sup>, Hadji HAMIDOU, MD<sup>6</sup>, Marc-André MAHE, MD, PhD<sup>1</sup>, Stéphane SUPIOT, MD, PhD<sup>1,4</sup>*

<sup>1</sup> Department of Radiation Oncology, ICO Cancer Center, Saint-Herblain, France

<sup>2</sup> Department of Biostatistics, ICO Cancer Center, Saint-Herblain, France

<sup>3</sup> Department of Medical Physics, ICO Cancer Center, Saint-Herblain, France

<sup>4</sup> CRCNA, Inserm U892, CNRS UMR 6299, Nantes, France

<sup>5</sup> Department of Radiation Oncology, Léon Bérard Center, Lyon, France

<sup>6</sup> Department of Radiation Oncology, ICO Cancer Center, Angers, France

**Correspondence:** Stéphane Supiot, Department of Radiation Oncology, ICO Cancer Center, Saint-Herblain, France, [stephane.supiot@ico.unicancer.fr](mailto:stephane.supiot@ico.unicancer.fr), Tel. : +33 240679900, Fax : +33 240679722

**Presented** at the American Society of Therapeutic Radiation Oncology 2015, San Antonio

**Acknowledgements:** funded by bourse Novartis du Groupe Européen d'Études des Métastases Osseuses (GEMO), Ligue contre le cancer (10/2010: Plate-Forme de Recherche Clinique du Cancéropôle Grand-Ouest).

Download English Version:

<https://daneshyari.com/en/article/8213537>

Download Persian Version:

<https://daneshyari.com/article/8213537>

[Daneshyari.com](https://daneshyari.com)